

Press release. Mölndal, 6 MAY 2021

## **Amferia AB Announces Partnership with Triolab AB to Launch Innovative Wound Care Products for Veterinary Applications**

**Amferia - an innovative medtech company developing novel antimicrobial wound care products, and Triolab AB - Sweden's largest distributor of premium medical & diagnostic devices has entered into a strategic partnership to jointly launch Amferia's antimicrobial wound care products for the Swedish veterinary market.**

**Christoffer Bento, Head of Sales at Triolab** – *“We are very excited to start this collaboration with Amferia to expand our offer to the veterinary clinics in Sweden. Amferia's innovative solutions for wound care will be very relevant to both clinics and animal owners to give the animals improved care while at the same time aiming to reduce antibiotic resistance. Moreover, working closely with a local company better opens up the possibility of having products suitable for our market.”*

The joint partnership with Triolab will enable Amferia to reach the large Swedish veterinary market where wound care and infection prevention is of prime importance, which has been intensified with the growing threat of antibiotic resistant infections. Amferia and Triolab's partnership will build on extensive data and feedback from Amferia's ongoing product trials across Europe. The joint efforts will aim to market the products to selective veterinary clinics across Sweden during 2021 and further expansion in 2022.

**Anand Rajasekharan, CEO of Amferia** – *“Triolab's solid market competence and leadership in the field will help spread Amferia's vision of addressing antibiotic resistant infections in veterinary care. We are absolutely inspired by this partnership, which helps bring our products to an area where there is considerable need for new solutions. Amferia's technology and products have already received strong interest and early positive feedback from veterinarians from around Europe, who immediately notice the potential of our products within wound and infection care.”*

== =

### **About Amferia and our Innovation**

Amferia was founded in 2018 and develops new antimicrobial materials for use in medical devices. The technology is based on bioinspired and amphiphilic antibacterial polymers that target and rapidly kill bacteria upon contact, including numerous antibiotic resistant bacteria like MRSA and MDR *E. Coli*. The material is highly selective and targets only bacteria while being entirely non-toxic to animal and human cells. Today, Amferia has transformed this concept into a first product of a preventive wound care patch for skin wound applications supported by strong scientific data and publications. Read more about the products, team, technology and publications at [www.amferia.com](http://www.amferia.com)

### **About Triolab**

Triolab AB is a leading distributor of premium medical and diagnostic devices for human and veterinary care. Founded in 1986, Triolab AB today has 55 employees, evenly distributed at the head office in Gothenburg and the office in Stockholm. Since 2016, Triolab belongs to the AddLife Group. Triolab has sister companies in Norway, Denmark and Finland, which together forms the Triolab Group - Nordic region's largest distributor in diagnostics, see <https://www.triolabvet.se>

== =

### **For more information, please contact:**

Anand Kumar Rajasekharan, CEO, Amferia AB, [anandk@amferia.com](mailto:anandk@amferia.com), +46 762981238

Christoffer Bento, Sales Manager, Triolab AB, [christoffer.bento@triolab.se](mailto:christoffer.bento@triolab.se), +46 31817205

== =